Shares climbed 3.5% post-earnings as solid 20% net sales growth, broad portfolio momentum, and pipeline advancement outpaced investor expectations. Management also unveiled multiple upcoming product launches and a refreshed executive team, supporting confidence in the company’s growth transition beyond Jakafi.

• First quarter revenue reached $1.27 billion, up 21% year-over-year, with net sales of $1.1 billion (+20%).
• Double-digit growth across all marketed products: Jakafi sales rose 7%, while the core business excluding Jakafi jumped 63% year-over-year.
• The company expects four new product launches within 12 months, including Jakafi XR (anticipated mid-year), Opzelura (European AD), Monjuvi (first-line DLBCL), and povorcitinib (HS).
• Positive late-stage pipeline momentum: FDA accepted povorcitinib application for HS ahead of schedule; Phase III studies underway in hematology, oncology, and immunology.
• Recent executive appointments—including a new CFO and expanded commercial leadership—aim to strengthen operational execution and launch readiness for 2026 and beyond.